Allon Therapeutics Inc NPCUF

Healthcare Biotechnology

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).

GREY:NPCUF - Post by User

Allon Therapeutics Inc

Bullboard Posts

Comment by diadon1945on Nov 30, 2010 4:34pm

279 Views

Post# 17779105

RE: RE: Parkinsons grant-another huge indication!

Yes! We have this $625,000 Parkinsons grant and another $500,000 U.S. government grant which was announced Nov.4! All of this in addition to the funding for the phase II/III PSP study. Don't be surprised if the company gets more reseach grants for Alzheimers and Schizophrenia studies. The grants in November are now at $1,125,000. Very nice.

Bullboard Posts

Investing with insurance and protection